Andrew Simon Bell

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2673306/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Sildenafil (VIAGRATM), a potent and selective inhibitor of type 5 cGMP phosphodiesterase with utility for the treatment of male erectile dysfunction. Bioorganic and Medicinal Chemistry Letters, 1996, 6, 1819-1824.	2.2	565
2	Fragment-derived inhibitors of human N-myristoyltransferase block capsid assembly and replication of the common cold virus. Nature Chemistry, 2018, 10, 599-606.	13.6	96
3	Novel antifungal 2-aryl-1-(1H-1,2,4-triazol-1-yl)butan-2-ol derivatives with high activity against Aspergillus fumigatus. Bioorganic and Medicinal Chemistry Letters, 1996, 6, 2031-2036.	2.2	85
4	Selective Inhibitors of Protozoan Protein N-myristoyltransferases as Starting Points for Tropical Disease Medicinal Chemistry Programs. PLoS Neglected Tropical Diseases, 2012, 6, e1625.	3.0	79
5	<i>N-</i> Myristoyltransferase as a potential drug target in malaria and leishmaniasis. Parasitology, 2014, 141, 37-49.	1.5	64
6	Structure-Based Design of Potent and Selective <i>Leishmania N</i> -Myristoyltransferase Inhibitors. Journal of Medicinal Chemistry, 2014, 57, 8664-8670.	6.4	56
7	Design of Second Generation Phosphodiesterase 5 Inhibitors. Current Topics in Medicinal Chemistry, 2007, 7, 405-419.	2.1	47
8	2(1H)-Quinolinones with cardiac stimulant activity. 1. Synthesis and biological activities of (six-membered heteroaryl)-substituted derivatives. Journal of Medicinal Chemistry, 1988, 31, 2048-2056.	6.4	44
9	2(1H)-Quinolinones with cardiac stimulant activity. 2. Synthesis and biological activities of 6-(N-linked,) Tj ETQq	1 1 0.7843 6.4	314.rgBT /Ov 4≄
10	The discovery of potent, selective, and orally bioavailable PDE9 inhibitors as potential hypoglycemic agents. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 2537-2541.	2.2	41
11	Diverse modes of binding in structures of <i>Leishmania majorN</i> -myristoyltransferase with selective inhibitors. IUCrJ, 2014, 1, 250-260.	2.2	38
12	Shaping a Screening File for Maximal Lead Discovery Efficiency and Effectiveness: Elimination of Molecular Redundancy. Journal of Chemical Information and Modeling, 2012, 52, 2937-2949.	5.4	36
13	High Throughput Screening Identifies Novel Lead Compounds with Activity against Larval, Juvenile and Adult Schistosoma mansoni. PLoS Neglected Tropical Diseases, 2016, 10, e0004659.	3.0	35
14	Challenges of drug discovery in novel target space. The discovery and evaluation of PF-3893787: A novel histamine H4 receptor antagonist. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 6596-6602.	2.2	32
15	Highly efficient diastereoselective Exo Diels-Alder reactions of homochiral 2-(N-acylamino)-1-thia-1,3-dienes: A powerful entry into optically pure thiopyrans. Tetrahedron Letters, 1996, 37, 123-126.	1.4	26
16	Structure-Guided Identification of Resistance Breaking Antimalarial N‑Myristoyltransferase Inhibitors. Cell Chemical Biology, 2019, 26, 991-1000.e7.	5.2	26
17	Identification, synthesis and SAR of amino substituted pyrido[3,2b]pyrazinones as potent and selective PDE5 inhibitors. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 4088-4091.	2.2	24
18	Novel phosphodiesterase type 5 modulators: a patent survey (2008 – 2010). Expert Opinion on Therapeutic Patents, 2011, 21, 1631-1641.	5.0	22

ANDREW SIMON BELL

#	Article	IF	CITATIONS
19	Generation and cycloadditions of 2-(N-acylamino)-1-thia-1,3-dienes part III: Control of diastereoselectivity using homochiral auxiliaries. Tetrahedron, 1998, 54, 3219-3234.	1.9	21
20	2(1H)-Quinolinones with cardiac stimulant activity. 3. Synthesis and biological properties of 6-imidazol-1-yl derivatives. Journal of Medicinal Chemistry, 1989, 32, 1552-1558.	6.4	17
21	Using a Non-Image-Based Medium-Throughput Assay for Screening Compounds Targeting N-myristoylation in Intracellular Leishmania Amastigotes. PLoS Neglected Tropical Diseases, 2014, 8, e3363.	3.0	16
22	Facile palladium catalysed functionalisation of 1,2-isothiazoline-3-ones. Tetrahedron Letters, 1994, 35, 6551-6554.	1.4	15
23	<scp>TAK</scp> 1 Inhibition in the <scp>DFG</scp> â€Out Conformation. Chemical Biology and Drug Design, 2013, 82, 500-505.	3.2	15
24	Novel Thienopyrimidine Inhibitors of <i>Leishmania N</i> -Myristoyltransferase with On-Target Activity in Intracellular Amastigotes. Journal of Medicinal Chemistry, 2020, 63, 7740-7765.	6.4	15
25	Synthesis of 1,2-disubstituted-3-alkylidenylpyrrolidines via a one-pot three-component reaction. Tetrahedron Letters, 2004, 45, 8511-8514.	1.4	14
26	Structure-guided optimization of quinoline inhibitors of Plasmodium N-myristoyltransferase. MedChemComm, 2017, 8, 191-197.	3.4	14
27	Facile palladium catalysed functionalisation of 1,2-isothiazoline-3-ones and the highly diastereoselective Diels-Alder reactions of 4-vinyl-1,2-isothiazoline-3-one-1-oxides. Tetrahedron, 1999, 55, 12313-12330.	1.9	13
28	7-Heteroaryl-1,2,3,5-tetrahydroimidazol[2,1-b]quinazolin-2(1H)-one derivatives with cardiac stimulant activity. Journal of Medicinal Chemistry, 1989, 32, 2042-2049.	6.4	11
29	Searching Chemical Space with the Bayesian Idea Generator. Journal of Chemical Information and Modeling, 2009, 49, 2211-2220.	5.4	11
30	The discovery of a novel series of compounds with single-dose efficacy against juvenile and adult Schistosoma species. PLoS Neglected Tropical Diseases, 2021, 15, e0009490.	3.0	11
31	Remarkably high diastereoselective exo diels-alder reactivity of 4-vinyl isothiazoline-3-one-1-oxides: The sulphoxide Syn effect Tetrahedron Letters, 1995, 36, 7713-7716.	1.4	8
32	Plate-based diversity subset screening: an efficient paradigm for high throughput screening of a large screening file. Molecular Diversity, 2013, 17, 319-335.	3.9	7
33	Discovery of a series of potent and selective human H4 antagonists using ligand efficiency and libraries to explore structure–activity relationship (SAR). Bioorganic and Medicinal Chemistry Letters, 2011, 21, 6591-6595.	2.2	6
34	Plate-based diversity subset screening generation 2: an improved paradigm for high-throughput screening of large compound files. Molecular Diversity, 2016, 20, 789-803.	3.9	6
35	Triazole Antifungals: Itraconazole (Sporanox®), Fluconazole (Diflucan®), Voriconazole (Vfend®), and Fosfluconazole (Prodif®). , 0, , 71-82.		3